A Phase 1/2 interventional study of Vapendavir in Healthy Males, sponsored by Altesa Biosciences, Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Altesa Biosciences, Inc. · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to assess how the body processes, breaks down and removes a new test medicine (vapendavir) from the body in healthy male participants.The main question it aims to answer is how the body handles the test medicine. In order to do that, the test medicine will be radiolabeled to track the test medicine in the body.
Healthy male participants who meet entry criteria will be admitted to the clinic for a duration of approximately 9 days (Day -1 to Day 8). Participants will be admitted in the evening on the day before dosing (Day -1). Participants will take a single oral dose of radiolabeled vapendavir on Day 1 and have samples collected and safety tests completed during various times throughout their stay in the the clinic. The safety tests will provide additional information on the safety and tolerability of the test medicine.
Altesa Biosciences, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of \[14C\]Vapendavir
Drug: Vapendavir
Single oral dose of \[14C\]vapendavir
To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])vapendavir.
Mass balance recovery of total radioactivity in all excreta (urine and feces): CumAe and Cum%Ae.
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
To determine the routes and rates of elimination of [14C]vapendavir.
Determination of routes and rates of elimination of \[14C\]vapendavir by Ae, %Ae, CumAe and Cum%Ae by interval.
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
To perform metabolite profiling and structural identification from plasma, urine and fecal samples.
Identification of the chemical structure of each metabolite accounting for greater than or equal to 10% of circulating radioactivity in plasma ("AUC pool"), and accounting for greater than or equal to 10% of the dose in urine (from urine pools) and feces (fecal homogenate pools) will be performed.
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
To identify the chemical structure of each metabolite accounting for more than 10% of circulating total radioactivity or accounting for 10% or more of the dose in excreta.
Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity or accounting for 10% or more of the dose in excreta.
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
To evaluate the extent of distribution of total radioactivity into blood cells.
Evaluation of whole blood: plasma concentration ratios for total radioactivity.
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Time prior to the first measurable concentration (Tlag)
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
To provide additional safety and tolerability information for vapendavir by assessing: incidence of adverse events (AEs), new physical examination findings and change from baseline for vital signs, electrocardiograms (ECGs), and laboratory safety tests.
Descriptive summaries for all safety data (AEs, vital signs, ECGs and safety laboratory assessments) will be provided.
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Time of maximum observed concentration (Tmax)
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Maximum observed concentration (Cmax)
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Area under the curve from time 0 to the time of last measurable concentration (AUC (0-last))
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Area under the curve from time 0 extrapolated to infinity (AUC (0-inf))
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Terminal elimination half-life (T1/2)
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
First order rate constant associated with the terminal (log-linear) portion of the curve (Ke)
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F)
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the cure extrapolated to infinity (AUCextrap)
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Mean residence time from time 0 to time of the last measurable concentration (MRT(0-last))
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Mean residence time from time 0 to extrapolated to infinity (MRT(0-inf))
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.
Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vd/F).
Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Mar 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vapendavir
Altesa Biosciences, Inc.